CHIA-CHI LINKUN-HUEI YEHCHIH-HSIN YANGCHIUN HSUYU-CHIEH TSAIHsu W.-L.ANN-LII CHENGCHIH-HUNG HSU2020-04-282020-04-2820070959-4973https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548244012&doi=10.1097%2fCAD.0b013e328051b3a3&partnerID=40&md5=d0f0597a6ed5dd6b642fa7471994823ahttps://scholars.lib.ntu.edu.tw/handle/123456789/487343This study assessed the clinical activity and safety of twice-weekly paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin (TP-HDFL) in patients with recurrent or metastatic esophageal squamous cell carcinoma. The regimen, composed of paclitaxel 35 mg/m 1-h intravenous infusion on days 1, 4, 8 and 11; cisplatin 20 mg/m 2-h intravenous infusion on days 2, 5, 9 and 12; and 5-flourouracil 2000 mg/m and leucovorin 300 mg/m 24-h intravenous infusion on days 5 and 12; repeated every 21 days. Forty-one patients (median age 51), 15 with de-novo metastatic disease and 26 with recurrent disease, were enrolled. Grades 3-4 neutropenia, leukopenia and diarrhea occurred in 37.8, 29.4 and 14.2% of cycles, respectively. One patient died of invasive fungal infection. Three complete responses, 13 partial response and 13 stable diseases were observed. The intent-to-treat response rate was 39.0% (95% confidence interval: 24-54). The median progression-free and overall survival were 6.3 and 8.9 months (range 1-50+), respectively. Twice-weekly TP-HDFL has the activity and toxicity profile similar to the previously reported same three-drug combination for advanced esophageal cancer. ? 2007 Lippincott Williams & Wilkins, Inc.[SDGs]SDG3cisplatin; dexamethasone; diphenhydramine; fluorouracil; folinic acid; paclitaxel; ranitidine; adult; alopecia; article; cancer combination chemotherapy; clinical article; clinical trial; confidence interval; continuous infusion; controlled study; diarrhea; drug activity; drug response; drug safety; esophageal squamous cell carcinoma; female; human; infection; leukopenia; liver toxicity; male; metastasis; mucosa inflammation; multiple cycle treatment; nausea and vomiting; nephrotoxicity; neurotoxicity; neutropenia; overall survival; priority journal; recurrent cancer; risk assessment; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxeljournal article10.1097/CAD.0b013e328051b3a3177624002-s2.0-34548244012